A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

BMC Cancer

Research Article

Jens Huober¹  Arthur Wischnik²  Andreas Rost³  Marcus Schmidt⁴  Hans-Joachim Lück⁵  Thomas Goehler⁶  Steffen Gerhardt⁷  Michael Neise⁸  Arnd Nusch⁹  Werner Fett^1,10 

[1] Breast Center Kantonsspital, St Gallen, Switzerland;Clinical Center Augsburg, Augsburg, Germany;Clinical Center Darmstadt, Darmstadt, Germany;Dept of Gynecology, University of Mainz, Mainz, Germany;Hannover Medical School, Hannover, Germany;Oncological Practice, Dresden, Germany;Oncological Practice, Gera, Germany;Oncological Practice, Krefeld, Germany;Oncological Practice, Velbert, Germany;Oncological Practice, Wuppertal, Germany;

关键词: Metastatic Breast Cancer;    Routine Clinical Practice;    Pegylated Liposomal Doxorubicin;    Clinical Benefit Rate;    Heart Palpitation;   

DOI  :  10.1186/1471-2407-10-2

 received in 2009-07-31, accepted in 2010-01-05,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundPegylated liposomal doxorubicin (PLD) is active in metastatic breast cancer. This observational study evaluated the efficacy and safety of PLD in patients treated during routine clinical practice.MethodsEligible patients had metastatic breast cancer and were treated with PLD according to the dose and schedule determined by their physician as part of routine practice. The primary objectives were to analyze the efficacy and toxicity of PLD therapy.Results125 patients were assessable. Median age was 62 years, 78% had performance status 0-1, and 60% had estrogen-receptor-positive disease. PLD treatment was second- or third-line in 69% of patients. Prior anthracyclines (adjuvant or metastatic) had been used in 56% of patients. The majority of patients (79%) received PLD every 4 weeks at a median dose of 40 mg/m2. Overall response rate was 43% in all patients and 34% in those previously treated with anthracyclines. The most common grade 3/4 adverse events were skin toxicity/hand-foot syndrome (6%), and leukopenia (3%).ConclusionsThis observational study supports the activity and tolerability of PLD in metastatic breast cancer as demonstrated in PLD clinical trials.

【 授权许可】

CC BY   
© Huober et al; licensee BioMed Central Ltd. 2010